Condensed Interim Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Expenses:
Research and development	$ 939,067	$ 897,305	$ 2,443,191	$ 2,778,100
General and administrative	964,676	1,035,140	2,998,127	3,232,248
Loss from operations	(1,903,743)	(1,932,445)	(5,441,318)	(6,010,348)
Other income:
Reimbursement grant income	183,281	236,226	536,744	661,062
Interest income	572	32,848	2,503	137,007
Misc other income	0	0	0	14,766
Foreign exchange loss	(29,574)	(4,841)	(54,294)	(9,681)
Nonoperating Income (Expense)	154,279	264,233	484,953	803,154
Loss before income taxes	(1,749,464)	(1,668,212)	(4,956,365)	(5,207,194)
Income tax expense	0	0	800	800
Net loss	(1,749,464)	(1,668,212)	(4,957,165)	(5,207,994)
Exchange differences on translation	164,611	1,612	119,536	(10,143)
Net comprehensive loss	$ (1,584,853)	$ (1,666,600)	$ (4,837,629)	$ (5,218,137)
Weighted average number of common shares (in shares)	7,022,678	3,221,806	5,217,343	3,180,647
Loss per common share - basic and diluted (in dollars per share)	$ (0.25)	$ (0.52)	$ (0.95)	$ (1.64)